Immunovant, Inc.
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed May 20, 2026
IMVT$35.71+1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
Immunovant, Inc.
Index to Consolidated Financial Statements
| Page | |
|---|---|
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 118 |
| Consolidated Financial Statements: | |
| Consolidated Balance Sheets as of March 31, 2026 and 2025 | 120 |
| Consolidated Statements of Operations for the Years Ended March 31, 2026, 2025 and 2024 | 121 |
| Consolidated Statements of Comprehensive Loss for the Years Ended March 31, 2026, 2025 and 2024 | 122 |
| Consolidated Statements of Stockholders’ Equity for the Years Ended March 31, 2026, 2025 and 2024 | 123 |
| Consolidated Statements of Cash Flows for the Years Ended March 31, 2026, 2025 and 2024 | 124 |
| Notes to Consolidated Financial Statements | 125 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.